Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Naoko Takebe, Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 14, pp. 3834-3844
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Targeting replication stress in cancer therapy
Alexandre André Balieiro Anastácio da Costa, Dipanjan Chowdhury, Geoffrey I. Shapiro, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 1, pp. 38-58
Closed Access | Times Cited: 193
Targeted therapy for osteosarcoma: a review
Shizhe Li, He Zhang, Jinxin Liu, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 9, pp. 6785-6797
Closed Access | Times Cited: 47
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Alvina I. Khamidullina, Yaroslav E. Abramenko, Alexandra V. Bruter, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1263-1263
Open Access | Times Cited: 21
Endometrial cancer: molecular classification and future treatments
Bradley R. Corr, Casey Cosgrove, Daniel Spinosa, et al.
BMJ Medicine (2022) Vol. 1, Iss. 1, pp. e000152-e000152
Open Access | Times Cited: 56
Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1
Amirali B. Bukhari, Gordon K. Chan, Armin M. Gamper
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 42
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification
Siqing Fu, Shuyang Yao, Yuan Yuan, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 9, pp. 1725-1734
Open Access | Times Cited: 40
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B. Allred, Li Chen, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 25, pp. 4154-4163
Closed Access | Times Cited: 25
Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents
Federica Martorana, Leandro Apolinário da Silva, Cristiana Sessa, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 953-953
Open Access | Times Cited: 30
Double‐strand DNA break repair: molecular mechanisms and therapeutic targets
Jinpeng Tan, Xingyao Sun, Hongling Zhao, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 23
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study
Alaa Embaby, Joachim Kutzera, Jill J.J. Geenen, et al.
Gynecologic Oncology (2023) Vol. 174, pp. 239-246
Closed Access | Times Cited: 21
Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases
Zhan‐Li Chen, Chen Xie, Wei Zeng, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy
Paulina Wdowiak, Joanna Matysiak, Piotr Kuszta, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 37
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review
Tim Schutte, Alaa Embaby, Neeltje Steeghs, et al.
Cancer Treatment Reviews (2023) Vol. 115, pp. 102531-102531
Open Access | Times Cited: 14
Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations
Koji Fukuda, Shinji Takeuchi, Sachiko Arai, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 6, pp. 101578-101578
Open Access | Times Cited: 5
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
Gerald S. Falchook, Jasgit C. Sachdev, Esteban Rodrigo Imedio, et al.
Investigational New Drugs (2023) Vol. 41, Iss. 3, pp. 493-502
Open Access | Times Cited: 12
Targeting WEE1 Kinase in Gynecological Malignancies
Wenhao Zhang, Qingli Li, Rutie Yin
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 2449-2460
Open Access | Times Cited: 4
Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease
Dawid Mehlich, Anna A. Marusiak
Cancer Letters (2022) Vol. 547, pp. 215775-215775
Closed Access | Times Cited: 18
Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
Michela Chiappa, Federica Guffanti, Martina Anselmi, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1807-1807
Open Access | Times Cited: 17
CCNE1Amplification as a Therapeutic Target
George Au‐Yeung, Linda Mileshkin, David D.L. Bowtell
Journal of Clinical Oncology (2023) Vol. 41, Iss. 9, pp. 1770-1773
Closed Access | Times Cited: 10
Structural and energetic insights into the selective inhibition of PKMYT1 against WEE1
Xuesen Qi, Guozhen Li, Jiahai Liu, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 6, pp. 3010-3018
Closed Access | Times Cited: 10
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers
Daehwan Kim, Heekyung Chung, Wen Liu, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
The RING Finger E3 Ligase RNF25 Protects DNA Replication Forks Independently of its Canonical Roles in Ubiquitin Signaling
Lilly Chiou, Deepika Jayaprakash, Gaith N. Droby, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Design, Synthesis, and Biological Evaluation of WEE1 degraders via HSP90-mediated Targeting Chimeras for Target Therapy of Acute Myeloid Leukemia
Xiaomei Li, Minmin Liu, Huijing Wang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 290, pp. 117512-117512
Closed Access
WEE1 Inhibition in Cancer Therapy: Mechanisms, Synergies, Preclinical Insights, and Clinical Trials
Krishnapriya Thangaretnam, Md Obaidul Islam, Jialun Lv, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104710-104710
Open Access
WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma
Rovingaile Kriska Ponce, Nicholas J. Thomas, Nam Q. Bui, et al.
JCI Insight (2022) Vol. 7, Iss. 6
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top